Press Releases

EndoBarrier Study Shows Improvement in Cardiovascular Risk

BOSTON and SYDNEY — 15 January 2020 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce positive EndoBarrier data from the University of Freiburg in Germany showing improvements of...

read more

Confirmation of Funding of 2019 Note and Issuance of Warrants

BOSTON and SYDNEY — 14 January 2020 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce that further to its announcements of 22 August 2019, 6 December 2019, 9 December 2019 and 17 December...

read more

Results of Adjourned Special Meeting

BOSTON and SYDNEY — 20 December 2019 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, held an adjourned Special Meeting of Stockholders on Thursday, 19 December 2019 at 5:00pm United States Eastern Standard Time...

read more

Results of Special Meeting

BOSTON and SYDNEY — 17 December 2019 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, today announces that it held a Special Meeting of Stockholders (Special Meeting) on Monday, 16 December 2019 at 5:00pm United...

read more

Exercise of Tranche 2 Warrants by Crystal Amber and Appendix 3B

BOSTON and SYDNEY — 4 October 2019 — GI Dynamics® Inc. (ASX:GID) (Company or GI Dynamics), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce that further to the announcements made by the Company on 22 August 2019 and 29...

read more

GI Dynamics Announces up to ~US$10 Million Financing with Crystal Amber – Defers Potential ASX Delisting – Extends Maturity Date of 2017 Convertible Note – General Corporate Update

BOSTON and SYDNEY — 22 August 2019 — GI Dynamics® Inc. (ASX:GID) (Company or GI Dynamics), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce that it has agreed to the terms of a financing (Financing) with Crystal Amber...

read more

Videos